Product image of Nifopress Retard (Nifedipine) supplied by GNH India

Nifopress Retard

Active Ingredient:
Nifedipine
Origin:
EU

Nifopress Retard (Nifedipine)

Nifedipine, the active ingredient in Nifopress Retard, is a calcium channel blocker presented as an oral formulation for oral use. It is employed to manage high blood pressure and to relieve chest pain caused by chronic stable angina in adult patients.
GNH India supplies Nifopress Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Crescent Pharma Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nifopress Retard acts on the cardiovascular system to control blood pressure and myocardial oxygen demand.

  • Hypertension: lowers systemic arterial pressure and reduces the workload on the heart.
  • Chronic stable angina: decreases the frequency and severity of chest pain by improving coronary blood flow.
  • Coronary vasospasm: prevents episodic constriction of coronary arteries, helping to avoid transient ischemic attacks.

How It Works

  • Nifedipine selectively blocks L‑type calcium channels in vascular smooth muscle and cardiac myocytes, inhibiting calcium influx. This causes arterial vasodilation, reduces peripheral resistance, and lowers myocardial oxygen consumption, thereby decreasing blood pressure and alleviating anginal symptoms.

Side Effects

Nifopress Retard may be associated with a range of adverse reactions.

Common Side Effects

  • Headache: mild to moderate intensity, often transient.
  • Flushing: warmth and redness, typically on the face or neck.
  • Peripheral edema: swelling of ankles or lower legs.
  • Dizziness or light‑headedness, especially on standing.
  • Tachycardia: increased heart rate.
  • Nausea or abdominal discomfort.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure requiring medical attention.
  • Myocardial infarction: rare occurrence of heart attack.
  • Arrhythmias: abnormal heart rhythms, including atrial fibrillation.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating therapy, several safety considerations should be observed.

  • Monitor blood pressure: regular measurements to ensure therapeutic effect.
  • Assess cardiac status: evaluate for ischemia or heart failure.
  • Avoid abrupt discontinuation: taper dose to prevent rebound hypertension.
  • Caution in hepatic impairment: dose adjustment may be necessary.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Nifopress Retard can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nifedipine plasma levels.
  • Concurrent use with other antihypertensives (e.g., beta‑blockers, ACE inhibitors): may cause excessive hypotension.
  • Grapefruit juice: can markedly raise drug concentrations.

Moderate Interactions (Monitor Closely):\n- Digoxin: may raise serum digoxin levels, requiring monitoring.

  • Simvastatin or other statins metabolised by CYP3A4: increased risk of myopathy.
  • Rifampin or other CYP3A4 inducers: may reduce nifedipine effectiveness.
  • Diuretics: can potentiate orthostatic hypotension.
  • Alcohol: may enhance vasodilatory effects, leading to dizziness.

Frequently Asked Questions

Nifopress Retard contains nifedipine, a calcium channel blocker that is prescribed to lower high blood pressure and to relieve chest pain in patients with chronic stable angina. It may also be used to prevent coronary artery spasms that can cause transient ischemic episodes.

Nifedipine blocks L‑type calcium channels in the smooth muscle of blood vessels and in cardiac cells. This inhibition reduces calcium entry, leading to vasodilation, lower peripheral resistance, and decreased myocardial oxygen demand, which together help control hypertension and angina.

The appropriate dose of Nifopress Retard is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety of nifedipine in pregnancy and lactation has not been fully established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nifopress Retard (nifedipine) belongs to the calcium channel blocker class, which primarily causes arterial vasodilation. Compared with beta‑blockers or ACE inhibitors, it may be preferred when a rapid blood‑pressure‑lowering effect is needed, but individual response and side‑effect profiles guide the choice of therapy.

Store Nifopress Retard at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Nifopress Retard is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, as this could affect the extended‑release properties of the formulation.

Serious risks include severe hypotension, myocardial infarction, life‑threatening arrhythmias, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, irregular heartbeat, or severe skin rash.

Patients with known hypersensitivity to nifedipine or any other calcium channel blocker should avoid Nifopress Retard. It is also contraindicated in individuals with severe aortic stenosis, unstable heart failure, or those taking certain strong CYP3A4 inhibitors without close medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.